Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: A systematic review

Multiple Sclerosis

Volumn 8, Issue 4, 2002, Pages 319-329

  Paisley, S ^a   Beard, S ^a   Hunn, A ^a   Wight, J P ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Baclofen; Dantrolene; Diazepam; Gabapentin; Multiple sclerosis; Spasticity; Systematic review; Threonine; Tizanidine

Indexed keywords

ANTICONVULSIVE AGENT; BACLOFEN; BOTULINUM TOXIN; CLONIDINE; CORTICOSTEROID DERIVATIVE; DANTROLENE; DIAZEPAM; GABAPENTIN; METHYLPREDNISOLONE; PLACEBO; SPASMOLYTIC AGENT; THREONINE; TIZANIDINE; VIGABATRIN; CENTRAL MUSCLE RELAXANT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISABILITY; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; HUMAN; MULTIPLE SCLEROSIS; MUSCLE STRETCHING; MUSCLE WEAKNESS; NAUSEA; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPASTICITY; TREATMENT OUTCOME; VERTIGO; XEROSTOMIA; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; HUMAN; MULTIPLE SCLEROSIS; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; SUPPORT, NON-U.S. GOV'T; HUMANS;

EID: 0035996216     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458502ms795rr     Document Type: Review

References (46)

1. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis
2. Social handicaps of multiple sclerosis and their relation to neurological alterations
3. Spasticity occurring in people with multiple sclerosis: Impact on health related quality of life
4. Preliminary trial of carisopodral in multiple sclerosis
5. Interrater reliability of a modified Ashworth scale of muscle spasticity
6. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS)
7. Functional evaluation: The Barthel Index
8. Assessing the quality of clinical trials: Is blinding necessary?
9. Baclofen for spasticity in multiple sclerosis: Double-blind crossover and three-year study
10. Effect of Baclofen on gait in spastic MS patients
11. The use of baclofen in treatment of spasticity in multiple sclerosis
12. A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis
13. A comparison of baclofen and diazepam in the treatment of spasticity
14. Liorseal, a new muscle relaxant in the treatment of spasticity - A double-blind quantitative evaluation
15. The effect of dantrolene sodium on spasticity in multiple sclerosis
16. Letter: Treatment of spasticity in multiple sclerosis with dantrolene
17. Comparison of dantrolene sodium and diazepam in the treatment of spasticity
18. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis
19. Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double-blind, placebo-controlled trial. US Tizanidine Study Group
20. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis
21. Correlations between dose, plasma concentrations, and anti-spastic action of tizanidine (Sirdalud registered)
22. Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy
23. Multicentre, double blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis
24. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis
25. The treatment of spasticity in multiple sclerosis: A double-blind trial of a new anti-spastic drug tizanidine compared with baclofen
26. A rating system for neurological impairment in multiple sclerosis
27. Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial
28. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis
29. An antispasticity effect of threonine in multiple sclerosis
30. Vigabatrin - A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy and disorders of motor control
31. Reflex changes induced clonidine in spinal cord injured patients
32. Clonidine in the treatment of spasticity in patients with multiple sclerosis
33. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects
34. Intensive immunosuppression in progressive multiple sclerosis
35. A neurologic rating scale (NRS) for use in multiple sclerosis
36. The MS impairment scale: A pragmatic approach to the assessment of the impairment in patients with multiple sclerosis
37. Assessment of cyclobenzaprine in the treatment of spasticity
38. Pendulousness of the legs as a diagnostic test
39. Intrathecal baclofen for severe spasticity
40. Clinical assessment of spasticity in spinal cord injury: A multi-dimensional problem
41. The impact of fatigue on patients with multiple sclerosis